BAYER AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.24 EUR | +0.66% |
|
+2.21% | -16.03% |
| May. 30 | German Shares Edge Up as Eurozone Sentiment Data Improves | MT |
| May. 30 | Burning Rock Biotech to Work With Bayer to Increase Patient Access to Precision Cancer Medicines in China | MT |
| Sales 2024 * | 47.12B 51.1B | Sales 2025 * | 47.9B 51.95B | Capitalization | 27.74B 30.09B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.33B 2.53B | Net income 2025 * | 3.18B 3.45B | EV / Sales 2024 * | 1.31 x |
| Net Debt 2024 * | 34B 36.88B | Net Debt 2025 * | 30.49B 33.07B | EV / Sales 2025 * | 1.22 x |
| P/E ratio 2024 * |
12.4
x | P/E ratio 2025 * |
8.66
x | Employees | 98,189 |
| Yield 2024 * |
0.39% | Yield 2025 * |
0.77% | Free-Float | 99.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bayer AG
More press releases
| 1 day | +0.66% | ||
| 1 week | +2.21% | ||
| 1 month | +3.25% | ||
| 3 months | +0.53% | ||
| 6 months | -9.95% | ||
| Current year | -16.03% |
1 week
26.92
28.37
1 month
26.9230.41
Current year
24.9636.09
1 year
24.9653.80
3 years
24.9667.99
5 years
24.9678.34
10 years
24.96146.45
| Managers | Title | Age | Since |
|---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 57 | 23-03-31 |
| Director of Finance/CFO | 55 | 18-04-25 | |
Bijoy Sagar
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Colleen Goggins
BRD | Director/Board Member | 68 | 17-03-31 |
Alberto Weisser
BRD | Director/Board Member | 68 | 21-03-31 |
Paul Achleitner
BRD | Director/Board Member | 67 | 02-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.77% | 70 M€ | -.--% | - | |
| 5.71% | 2 M€ | +13.56% | - | |
| 4.28% | 962 M€ | -.--% | - | |
| 4.10% | 0 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 28.24 | +0.66% | 5,104,857 |
| 24-05-30 | 28.06 | +4.20% | 3,871,814 |
| 24-05-29 | 26.92 | -3.15% | 4,090,346 |
| 24-05-28 | 27.8 | -1.66% | 3,407,151 |
| 24-05-27 | 28.27 | +2.32% | 2,309,474 |
Delayed Quote Xetra, May 31, 2024 at 11:36 am EDT
More quotes
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows:
- agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.;
- pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.;
- OTC products and nutritional supplements (12.7%);
- other (0.5%).
Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).
Sector
Pharmaceuticals
Calendar
2024-08-06
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
28.24
EUR
Average target price
36.64
EUR
Spread / Average Target
+29.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.03% | 30.09B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- BAYN Stock
